SYRE Latest Press Releases

-- October 18, 2026 --

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026 Globe Newswire 9:30 AM

-- October 5, 2026 --

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock Globe Newswire 8:13 PM

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock Globe Newswire 4:01 PM

-- October 2, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- September 8, 2026 --

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations Globe Newswire 8:00 AM

-- September 4, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:01 PM

-- September 3, 2026 --

Spyre Therapeutics to Participate in Upcoming September Investor Conferences Globe Newswire 4:05 PM

-- August 25, 2026 --

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 Globe Newswire 4:01 PM

-- August 10, 2026 --

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa Globe Newswire 8:00 AM

-- August 7, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- August 4, 2026 --

Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:02 PM

-- July 2, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- June 15, 2026 --

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients Globe Newswire 8:00 AM

-- June 5, 2026 --

Spyre Therapeutics Announces Grants of Inducement Awards Globe Newswire 4:01 PM

-- June 3, 2026 --

Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA Globe Newswire 8:00 AM

-- May 28, 2026 --

Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation Globe Newswire 8:35 AM

Market Data Delayed 15 Minutes